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Objective: Opinions of patients and neurologists about aspects of their epilepsy and their treatment were compared.
Method: Thirty-two neurologists, working in general hospitals, included 198 patients aged 16 years or more. Both neurologist and
patient independently completed a questionnaire consisting of simple open questions about the epilepsy and the drug treatment.
The average characteristics for this group are very similar to characteristics of the general population: age and gender distribution,
highest completed educational level, occupational participation and family circumstances are not statistically significant from
the general population.
Results: Neurologists and patients appear to agree about most areas that we assessed: seizure count, severity of epilepsy, efficacy
and tolerability of the treatment and impact of the epilepsy and treatment on daily life (as expressed in the ‘Quality of Life
ratings’). Detailed analysis showed that this agreement is partly artificially increased by the group with good outcome and
less strong or even absent for the more severe epilepsies. For seizure count, we see 96.4% agreement for the group with low
seizure frequency and 73.1% agreement in case of high seizure frequency. For the evaluation of severity of the epilepsy, 73.2%
agreement is found for mild classification and 16.6% agreement for the severe classification. Agreement on Quality of Life
(QOL) is almost complete in patients with excellent QOL (91% agreement) and almost absent for a low QOL (17% agreement).
Finally, the same pattern is found for reports on side-effects of the medication. Both neurologists and patients report side-effects
in about 40% of the cases. This suggests excellent agreement but individual data show that agreement is only satisfactory for
the milder epilepsies (16.2% vs. 16.2%). For the more severe agreement is almost absent (4.1% of the neurologists vs. 13.4%
of the patients).
Discussion: Possibly, it is more difficult for the neurologist to perceive and appraise all relevant factors in the case of complex
epilepsies. Alternatively, subjective definitions and assumptions of patients differ from the standards set by the neurologists in
the case of continuing seizures.
The clinical relevance of our findings is that, especially in the cases of more severe and refractory epilepsies, patients’ opinions
are of utmost importance and we cannot take our own opinions and evaluations at face value.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Treatment of epilepsy will be influenced by the com-
plex interactions between the patient and his or her
neurologist. Because subjective factors are an essen-
tial mediator in this interaction, both parties may have
different perspectives and goals: Are suppressing
seizures or avoiding side-effects the most important
aim of the treatment? Is 1 seizure per month accept-
able or not? Is having a seizure affecting ‘Quality of
Life’? To what extent are side-effects of the treat-
ment acceptable? Such treatment decisions have to
be based on subjective information provided by the
patient, influenced by the—often implicit—goals
set by the patients1–3. Gold standards for important
treatment criteria, such as occurrence, severity and
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tolerability of side-effects, are seldomly available
or—if available—valid4, 5. Correlation between the
‘objective measurements by tests’ and the subjective
opinion of the patient or his treating physician is gen-
erally low in all kind of clinical populations6–8. Even
counting seizures may seem to be easy, but many
studies have questioned the reliability and accuracy
of seizure counts even when controlled seizure diaries
are used9.
So far, it is unknown to what extent neurologists and
patients agree or disagree about the epilepsy, and about
success or failure of treatment. Instead of correlating
the opinions of patients with some gold standard, we
compared the subjective opinion of patients with the
subjective opinion of the neurologists on general as-
pects of their epilepsy and their treatment. Our study
is based on patients with epilepsy treated in general
hospitals in The Netherlands.
METHOD
Neurologists in general hospitals were asked to partic-
ipate in this study. These neurologists were randomly
selected from the neurologists working in general hos-
pitals in The Netherlands. They were asked to hand
over a questionnaire to each consecutive patient (up to
20 patients) aged 16 years or more with a confirmed
diagnosis of epilepsy that visited their outpatient de-
partment in the period mid to end 2000. Patients with
insufficient knowledge of the Dutch language were ex-
cluded. Each neurologist could include a maximum of
20 patients. In total, 32 neurologists accepted to partic-
ipate and 264 patients received the questionnaires (on
average about 8 patients per neurologist) of which 198
were returned (response rate of 76%). The sample size
is sufficiently large to allow generalisation of the find-
ings to the total population of patients under the care
of neurologists working in general hospitals10, 11. In
addition, the neurologists were also requested to com-
plete a questionnaire about the patients that received
a questionnaire. This was done independently of the
patients. The questionnaire consisted of simple open
questions about the epilepsy and the drug treatment.
The Quality of Life (QOL) rating used the Qolie-1012.
The study was conducted in accordance with the
ICH GCP guideline (1997) and approved by an in-
dependent ethics committee. Subjects gave written
informed consent before entering the study.
RESULTS
To control whether the sample is representative, we
compared the demographic characteristics of our sam-
ple with the general population:
Table 1: Age distribution of the study population versus the
general population.
% study sample % general population
16–29 years 14 18
30–49 years 40 32
50–65 years 28 17
>65 years 14 13
Fig. 1: Age distribution for the study sample and general
population.
Mean age of the study population was 46.7 years
(SD 16.1). Table 1 shows that the age distribution in
our study sample is representative for the general pop-
ulation in The Netherlands13 (Chi-square = 2.682;
df = 3; P ≥ 0.50).
Fig. 1 illustrates the concurrence of both age distri-
butions:
Gender distribution was 55% male versus 45% fe-
male, which is not significantly different from the
general population in The Netherlands13.
Table 2 shows the highest completed educational
level of the patients compared to the distribution of
highest completed educational level in the general
population in The Netherlands13.
Although there is an overrepresentation of lower ed-
ucational levels in our study sample, compared to the
general population, the difference is not statistically
significant (Chi-square = 6.173; df = 4; P ≥ 0.10).
In total, 41.6% of the patients have a full-time employ-
ment and 8.5% have paid part-time jobs. This is not
statistically significant different from the general pop-
ulation (56% of the Dutch population aged >16 have a
paid job of at least 12 hours per week13; Chi-square =
0.0009; P = 0.99).
The family circumstances of our patients are similar
to those in the general population as shown in Table 3
(Chi-square = 0.250; df = 2; P = 0.98).
Table 2: Highest completed educational level for patients in
our study versus the general population.
% patients in % in the general
the study sample population
Primary education 10.9 4
Lower vocational training 24.1 22
Lower secondary education 32.6 40
Higher secondary education 7.6 9
Higher education 14.6 25
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Table 3: Family circumstances for patients in our study
versus the general population.
% patients in % in the general
the study sample population
No partner/living single 30.9 34
Partner 42.4 39
Partner with children 26.7 27
The majority of the patients in our sample (55.3%)
had generalised seizures (either primarily generalised
or secondarily generalised), 15% had simple partial
seizures and 34.5% complex partial seizures. The
average period from seizure onset to the present visit
in the hospital is 13 years for the age group until 29
years, 17 years for the age group 30–49 years and
23 years for the age group 50–65 years. For the age
group >65 years, the period since epilepsy onset is
somewhat smaller (20 years), due to the relative large
group with an epilepsy onset at later age. The ma-
jority of these patients (77.6%) visit the neurologists
at least once or twice per year; the remainder group
(22.4%) only come to the hospital in case of prob-
lems. Most patients use monotherapy of antiepileptic
drugs (AEDs) (68.3%), 29.6% have polytherapy and
four patients do not use any medication (but still visit
the outpatient department of the hospital). Valproate
is the most frequent used AED and is used in 40% of
the patients; carbamazepine is used in 28.4% of the
patients (combined with oxcarbazepine this is 36.7%),
phenytoin in 9.1% of the patients and phenobarbital
in 5.3% of the patients. The newer AEDs are only
used in small percentages of the patient group (<2%).
Most patients are on unchanged treatment during the
last 12 months (74.4%). Almost all patients report
satisfactory compliance.
Comparison between the patients and
neurologists reports
Seizure frequency
Agreement between the patients and neurologists for
the number of seizures that occurred during the last
year was excellent (Table 4).
Table 4: Number of seizures during the last year according
to patients and neurologists.
% according to % according to
patient opinion neurologist opinion
Seizure free >1 year 55.8 57.9
1–3 seizures per year 23.2 25.4
4–11 seizures per year 12.0 9.9
12–20 seizures per year 4.4 4.3
>20 seizures per year 4.6 2.5
Table 5: Results for ranking of severity of epilepsy for
patients versus neurologists.
Severity Severity
according to according to
patient neurologist
% score: 1, 2 (mild) 58.4% 62.7%
% score: 3–5 (average) 33.3% 28.8%
% score: 6, 7 (severe) 4.4% 4.8%
Average rank (range 1–7) 2.58 (1.89) 2.59 (1.76)
Missing 3.9% 3.7%
Spearman’s Rho shows a statistically significant cor-
relation for the comparison between the patients and
neurologists as a group (correlation = 0.83; P ≤
0.001). Looking at the agreement per individual, the
percentage agreement is highest for the patients who
are seizure free (96.4% agreement between the pa-
tients and neurologists for the patients who are seizure
free for >1 year) and lower for the other (smaller) cat-
egories. For the patients with high seizure frequency
(>12 seizures per year), the percentage agreement is
73.1%.
Severity of the epilepsy
A subjective impression for the severity of the epilepsy
was scored independently by the patients and the neu-
rologists on a scale ranging from 1 = mild to 7 =
severe (Table 5).
Agreement between the neurologists and the pa-
tients as a group for subjectively rated severity of
the epilepsy is good, although there is less agreement
than for seizure count (non-parametric Spearman’s
Rho = 0.28; P ≤ 0.001). The agreement per individ-
ual patient is not as strong as for the seizure frequency
and artificially high due to the agreement for the large
groups that have a ‘mild’ classification (73.2% agree-
ment between the neurologists and patients). Agree-
ment for the ‘severe’ classification is lower (16.6%).
Additional complaints
In total, 70% of the patients have additional complaints
besides the seizures. Most frequent complaints are the
related areas of fatigue, somnolence, attentional prob-
lems (‘feeling less alert’). Memory is also a frequent
problem (about one third of the patients). For most
areas the patients indicate that they are not able to re-
late this to a cause. Gum problems, weight gain and
somnolence are associated with the AED treatment.
Speech problems are predominantly seen as an effect
of the epilepsy. Table 6 summarises these problems.
If we isolate the percentage of patient complaints
that they see as an adverse effect of the antiepileptic
treatment and compare this to the percentage of side-
effects reported by the neurologists, the respective
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Table 6: Complaints mentioned by the patients as well as the probable cause (patient report).
Total (%) Seen by the patients as caused by
Side-effect AED Epilepsy Unknown cause
Fatigue 36 25 22 53
Attentional problems 34 27 21 52
Somnolence 33 51 13 36
Memory problems 33 19 26 56
Headache 29 7 28 66
Tremor 27 30 30 40
Slowing 23 27 25 48
Weight gain 19 58 0 42
Dizziness 19 15 49 36
Gum problems 15 50 0 50
Speech difficulties 14 7 55 38
Walking difficulties 13 11 36 54
Decreased possibilities 12 15 31 54
Visual problems 11 25 29 46
Aggression 11 13 13 74
Depression 10 10 19 71
No complaints 30
Items representing >50% of the patients in bold.
Table 7: Quality of Life (QOL) as reported by the patient versus neurologist opinion.
QOL as reported QOL of the patient as observed
by the patient by the neurologist
% high QOL (score: 1, 2) 79.0% 85.5%
% average QOL (score: 3) 14.9% 10.2%
% low QOL (score: 4, 5) 6.1% 4.3%
Average score (1–5), 1 = excellent;
5 = worst possible
2.01 (0.8) 1.78 (0.8)
Table 8: Percentage agreement on Quality of Life (QOL) estimation by neurologist and patient.
Patient Neurologist
Excellent Average Worst possible Total (N)
Excellent n = 139 (91%) n = 10 n = 4 153
Average n = 17 n = 9 (31%) n = 3 29
Worst possible n = 9 n = 1 n = 2 (17%) 12
Total (N) 165 20 9 194
percentages (41.7% for the patients and 42.6% for
the neurologists) show a statistically significant cor-
relation (Rho = 0.57; P ≤ 0.001). Neurologists and
patients as a group therefore agree on the occurrence
of side-effects. Again, there is statistically signif-
icant disagreement in the severe types of epilepsy
(where more patients use polytherapy): 4.1% of
the neurologists report side-effects in their patients
whereas 13.4% of the patients report side-effects
(Chi-square = 13.752; df = 1; P ≤ 0.001).
Quality of Life
The average rating of QOL (ranging from 1 =
excellent to 5 = worst possible) is excellent for the
majority of the patients (2.01: patient report). The
correlation between the patients and neurologists
as a group is statistically significant (Rho = 0.45;
P ≤ 0.001) with a somewhat more positive evalu-
ation of QOL by the neurologists, compared to the
patients (Table 7).
The agreement per individual patient (Table 8), how-
ever, shows that the agreement is largest for ‘excellent’
QOL (91% agreement), and almost absent in case of
low QOL (17%).
DISCUSSION
We studied a sample of 198 patients with epilepsy
treated in general hospitals. The average characteris-
tics for this group are very similar to characteristics of
the general population: age and gender distribution,
highest completed educational level, occupational
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participation and family circumstances are not statisti-
cally significant different from the general population.
There is a trend—even in this group with uncom-
plicated epilepsy—for a somewhat lower achieved
educational level.
The majority of the patients are seizure free (57.9%)
and another one fourth of the sample have only a few
seizures per year; 83.3% of this group may therefore
be considered well controlled. This is in line with
the results of epidemiological studies in the group of
patients with uncomplicated epilepsy14. About 70%
of the patients in our study use monotherapy and are
mostly treated with valproate (40% of the patients)
or carbamazepine (29% of the patients, combined
with oxcarbazepine this is 36.7%). Remarkably, only
small percentages of the patients use the newer AEDs
(all <2%).
Neurologists and patients as a group appear to agree
about most areas that we assessed: seizure count,
severity of epilepsy, efficacy and tolerability of the
treatment and impact of the epilepsy and treatment
on daily life (as expressed in the ‘Quality of Life
ratings’). This is reassuring for clinical practice, given
the dependency of treatment choices on agreement
about success and failure of treatment. Nonetheless,
some additional comments have to be made. The
excellent agreement may be caused by the fact that
most patients were treated for a considerable period
of time and the results would then represent the result
of the communication between the neurologists and
their patients over time. Nonetheless, if we inspect
the individual comparisons between each patient and
his or her treating neurologist, then the agreement ap-
pears only high for those patients with mild epilepsy
and good outcome, whereas this agreement is less
strong or even absent for the more severe epilepsies.
For seizure count, we see 96.4% agreement for the
patients with low seizure frequency and 73.1% agree-
ment in case of high seizure frequency; for severity
of the epilepsy, 73.2% agreement is found for mild
classification and 16.6% agreement for the severe
classification. This is probably an effect of differences
in the ‘subjective definition’ of severity between the
neurologists and patients. It is conceivable that both
‘parties’ have different criteria and assumptions here.
The same lack of agreement is seen for the evaluation
of the overall psychosocial situation of the patients,
expressed in ‘Quality of Life estimates’. Neurologists
seem to be able to estimate the subjective ‘Quality
of Life’ of the patients as a group. This agreement
is, however—as for the other areas—artificially in-
creased in our study by the excellent treatment results
in this specific patient population with almost 60%
of the patients being seizure free. Earlier studies
showed a high correlation between the seizure con-
trol and QOL and the major factor contributing to
QOL in patients with epilepsy was seizure frequency,
specifically whether patients are seizure free or not15.
Our study in patients with uncomplicated epilepsy
does not rule out the possibility that the agreement
between the patients and neurologists is much lower
in refractory epilepsy. Agreement on QOL is almost
complete in patients with excellent QOL (91% agree-
ment) but almost absent for patients with a low QOL
(17% agreement). Finally, the same pattern is found
for reports on side-effects of the medication. Both
neurologists and patients report side-effects in about
40% of the cases. This suggests excellent agreement,
but individual data show that agreement is only satis-
factory for the milder epilepsies (16.2% vs. 16.2%).
For the more severe epilepsies (were most patients
use polytherapy), agreement is almost absent, with
4.1% of the neurologists and 13.4% of the patients
reporting side-effects. This disagreement between
the neurologists and patients in cases of more se-
vere epilepsies may be partly due to differences in
‘subjective definition’ of severity (we asked for a sub-
jective rating of severity), although the consistency
of the discrepancy (occurring not only in the case of
high severity ranking, but also in high seizure fre-
quency and low QOL scores) points to the fact that
differences in subjective perspectives and goals of
treatment have a greater impact in more complicated
epilepsies and treatments.
ACKNOWLEDGEMENT
This study was supported by an unrestricted educa-
tional grant from GlaxoSmithKline, The Netherlands.
REFERENCES
1. Carpay, J. A., Arts, W. F. M., Geerts, A. et al. Epilepsy in
childhood: an audit of clinical practice. Archives of Neurology
1998; 55: 668–673.
2. Aldenkamp, A. P., Alpherts, W. C. J., Sandstedt, P. et al.
Antiepileptic drug-related cognitive complaints in seizure-free
children with epilepsy before and after dug discontinuation.
Epilepsia 1998; 39 (10): 1070–1074.
3. Collaborative Group for Epidemiology of Epilepsy. Adverse
reactions to antiepileptic drugs: a multicenter survey of clin-
ical practice. Epilepsia 1986; 27 (4): 323–330.
4. Marson, A. G., Kadir, Z. A., Hutton, J. L. and Chadwick,
D. W. The new antiepileptic drugs: a systematic review of
their efficacy and tolerability. Epilepsia 1997; 38 (8): 859–
880.
5. Greenwood, R. S. Adverse effects of antiepileptic drugs.
Epilepsia 2000; 41 (S. 2): 42–52.
6. The Lancet. ‘Doing Better, Feeling Worse; Editorial Com-
ments. 1990; 336: 1037–1038.
7. Aldenkamp, A. P., Vermeulen, J., Alpherts, W. C. J., Overweg,
J., Van Parijs, J. A. P. and Verhoeff, N. P. L. G. Validity of
computerized testing: patient dysfunction and complaints ver-
sus measured changes. In: Assessment of Cognitive Function
528 A. P. Aldenkamp & C. Van Donselaar
(Eds W. E. Dodson and M. Kinsbourne). New York, Demos,
1992; pp. 51–68.
8. Piazzini, A., Canevini, M. P., Maggiori, G. and Canger,
R. The perception of memory failures in patients with
epilepsy. European Journal of Neurology 2001; 8: 801–
808.
9. Scott-Lennox, J., Bryant-Comstock, L., Lennox, R. and Baker,
G. A. Reliability, validity and responsiveness of a revised scor-
ing system for the Liverpool Seizure severity scale. Epilepsy
Research 2001; 44: 55–63.
10. Cohen, J. Statistical Power Analysis for the Behavioral
Sciences. New York, Academic Press, 1977.
11. Cook, D. and Campbell, D. T. Quasi-Experimentation; Design
& Analysis Issues for Field Settings. Boston, Houghton Mifflin
Company, 1979.
12. Cramer, J. A. Quality of life assessment in clinical practice.
Neurology 1999; 53 (S. 2): 49–52.
13. CBS-Statistisch Jaarboek, ISBN 903572925 0. Den Haag, Sdu
Servicecentrum Uitgevers, 2002.
14. Duncan, J. S., Shorvon, S. D. and Fish, D. R. Clinical
Epilepsy. New York, Churchill Livingstone, 1995.
15. Baker, G. A., Jacoby, A., Buck, D., Stalgis, C. and Monnet,
D. Quality of life of people with epilepsy: a European Study.
Epilepsia 1994; 35: 608–615.
